Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2 billion.

赛诺菲已获得诺瓦克斯新型冠状病毒疫苗的联合商业许可，并将与生物技术公司合作开发价值高达12亿美元的流感/新型冠状病毒联合疫苗。

The new agreement – which includes an upfront payment of $500 million – will help to deflect criticism levelled at Novavax by one of its top investors, claiming it has failed to make the most of its COVID shot and other vaccine technologies.

这项新协议包括5亿美元的预付款，将有助于转移Novavax的一位顶级投资者对Novavax的批评，该投资者声称Novavax未能充分利用其新型冠状病毒疫苗和其他疫苗技术。

Sanofi – which has taken a sub-5% equity stake in Novavax for $70 million – said the alliance will expand access to the biotech’s protein-based adjuvanted COVID vaccine Nuvaxovid/Covovax from next year onwards. The license covers the entire world except in markets such as India, Japan, and South Korea where agreements are already in place..

赛诺菲（Sanofi）以7000万美元收购了Novavax 5%以下的股权。赛诺菲表示，该联盟将从明年起扩大对生物技术公司基于蛋白质的佐剂新型冠状病毒疫苗Nuvaxovid/Covax的获取。该许可证覆盖了整个世界，但印度、日本和韩国等市场已达成协议。。

The two companies will also collaborate on the development of a novel flu-COVID combination vaccine, based on authorised vaccines, which would be solely commercialised by Sanofi if approved.

两家公司还将合作开发基于授权疫苗的新型流感-新型冠状病毒联合疫苗，如果获得批准，该疫苗将由赛诺菲独家商业化。

“With flu and COVID-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-COVID-19 combination vaccines offering patients both enhanced convenience and protection against two serious respiratory viruses,” said Jean-Francois Toussaint, Sanofi’s global head of vaccines R&D..

赛诺菲全球疫苗研发负责人让·弗朗索瓦·图桑（Jean-Francois Toussaint）表示：“流感和新型冠状病毒的住院率现在已经紧密相映，我们有机会开发非mRNA流感-新型冠状病毒联合疫苗，为患者提供更大的便利性和针对两种严重呼吸道病毒的保护。”。。

The French pharma group noted multiple times in its announcement of the alliance that Novavax’s vaccine platform isn’t based on mRNA. Activist investor Shah Capital – which has lobbied for changes at the company – has repeatedly asserted that greater effort should be taken at Novavax to promote its shot as an alternative for patients who may be nervous about getting vaccinated with mRNA products..

这家法国制药集团在宣布结盟时多次指出，诺瓦克斯的疫苗平台不是基于mRNA。积极投资者沙阿资本（Shah Capital）曾游说该公司进行改革，并一再声称诺瓦克斯应加大力度，推广其疫苗，作为可能对接种mRNA产品感到紧张的患者的替代方案。。

Shah Capital also said that Novavax wasn’t making the most of its Matrix-M adjuvant technology, so it is perhaps notable that Sanofi has also taken a non-exclusive license to that for use in its vaccine products.

Shah Capital还表示，Novavax没有充分利用其Matrix-M佐剂技术，因此可能值得注意的是，赛诺菲还获得了用于其疫苗产品的非独家许可。

Novavax has previously said that it is expecting phase 3 results for a COVID/flu vaccine in the second half of this year, with a launch slated for 2026, and the agreement with Sanofi points to the potential for multiple combinations. Sanofi is one of the world’s top producers of flu vaccines with sales of €2.7 billion ($2.9 billion) last year..

Novavax此前曾表示，预计今年下半年新型冠状病毒/流感疫苗的第三阶段结果将于2026年推出，与赛诺菲的协议指出了多种组合的潜力。赛诺菲是全球最大的流感疫苗生产商之一，去年销售额为27亿欧元（29亿美元）。。

Novavax meanwhile achieved revenues of $1 billion in 2023 from its COVID vaccine and has said it expects to make $800 million to $1 billion this year after delivering an updated version of the shot for the autumn vaccination season.

与此同时，Novax在2023年从新型冠状病毒疫苗中获得了10亿美元的收入，并表示，在为秋季疫苗接种季节提供了最新版本的疫苗后，预计今年将获得8亿至10亿美元的收入。

The deal with Sanofi includes up to $700 million in development, regulatory and launch milestones, as well as double-digit percentage royalties on sales of COVID and flu-COVID combination vaccines.

与赛诺菲的交易包括高达7亿美元的开发、监管和发布里程碑，以及销售新型冠状病毒和流感-新型冠状病毒联合疫苗的两位数版税。

“This collaboration is important for Novavax and for global public health,” said Novavax’s chief executive John Jacobs. “Together, we can broaden access to both our COVID-19 vaccine and our adjuvant to ensure more individuals can benefit from the protection vaccines can provide.”

Novavax首席执行官约翰·雅各布斯（JohnJacobs）表示：“这种合作对于Novavax和全球公共卫生都很重要。”。“共同努力，我们可以扩大新型冠状病毒疫苗和佐剂的使用范围，以确保更多的人能够从疫苗所能提供的保护中受益。”